These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37884699)

  • 1. Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer.
    Ham WS; Park JS; Jang WS; Kim J
    Ann Surg Oncol; 2024 Feb; 31(2):1384-1392. PubMed ID: 37884699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
    Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
    BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
    Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
    BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy.
    Gakis G; Ngamsri T; Rausch S; Mischinger J; Todenhöfer T; Schwentner C; Schmid MA; Hassan FA; Renninger M; Stenzl A
    World J Urol; 2015 Oct; 33(10):1429-37. PubMed ID: 25595732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
    Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete Transurethral Resection before Radical Cystectomy May Improve Oncological Outcomes.
    Graffeille V; Verhoest G; Gryn A; Kammerer-Jacquet SF; Alimi Q; Beauval JB; Beuzit L; Pradère B; Thoulouzan M; Khene ZE; Guille F; Rioux-Leclercq N; Mathieu R; Gamé X; Bensalah K; Soulié M; Roumiguié M; Peyronnet B
    Urol Int; 2022; 106(2):122-129. PubMed ID: 33626547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients With Muscle-Invasive Bladder Cancer With Lymphovascular Invasion in Transurethral Resection Specimen Benefits Most From Platinum-Based Neoadjuvant Chemotherapy.
    Wang Z; He W; Ying Y; Wang M; Chen Q; Zhang Z; Zeng S; Xu C
    Clin Genitourin Cancer; 2024 Apr; 22(2):201-209.e7. PubMed ID: 37989709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer.
    Zhiyu Z; Qi Z; Zhen S; Jun O; Jianglei Z
    Technol Cancer Res Treat; 2021; 20():15330338211062323. PubMed ID: 34816789
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
    Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
    World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only.
    Cajipe M; Wang H; Elshabrawy A; Kaushik D; Liss M; Svatek R; Wu S; Chowdhury WH; Ramamurthy C; Mansour AM
    Urol Oncol; 2020 Apr; 38(4):231-239. PubMed ID: 31956078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
    Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
    JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
    BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
    Tang Y; Lin L; Xiao Y; Meng L; Yang Y; Li X
    Clin Transl Oncol; 2024 Feb; 26(2):446-455. PubMed ID: 37389736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
    Zhou YX; Hu QC; Zhu YJ; Mu XL; Liu JY; Chen Y
    Eur J Med Res; 2023 Oct; 28(1):422. PubMed ID: 37822001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder cancer.
    James AC; Lee FC; Izard JP; Harris WP; Cheng HH; Zhao S; Gore JL; Lin DW; Porter MP; Yu EY; Wright JL
    Clin Genitourin Cancer; 2014 Aug; 12(4):287-91. PubMed ID: 24560087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.
    Su X; Dong C; Liao W; Liu W
    World J Surg Oncol; 2023 Aug; 21(1):271. PubMed ID: 37641150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and oncological outcomes of urethral recurrence in male patients with muscle invasive bladder cancer after radical cystectomy combined with urinary diversion: a propensity score-matched case control study.
    Yao Z; Jiang Y; Zhu X; Wu B; Bai S
    Int J Clin Oncol; 2020 Jul; 25(7):1377-1384. PubMed ID: 32318904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.
    Kang NW; Feng YH; Lin KL; Chen YC; Ho CH; Yang CC
    Cancer Med; 2024 Jan; 13(2):e6972. PubMed ID: 38379322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.